Showing 1 to 2 of 2 results


France's HAS Rejects Accelerated Approval for Alzheimer's Drug Leqembi
France's Haute Autorité de santé (HAS) rejected accelerated approval for Biogen and Eisai's Alzheimer's drug Leqembi due to modest efficacy and concerning side effects, despite its EU approval and patient advocacy.
France's HAS Rejects Accelerated Approval for Alzheimer's Drug Leqembi
France's Haute Autorité de santé (HAS) rejected accelerated approval for Biogen and Eisai's Alzheimer's drug Leqembi due to modest efficacy and concerning side effects, despite its EU approval and patient advocacy.
Progress
16% Bias Score

Leaked French Gender Transition Guidelines Spark Controversy
The French High Authority of Health (HAS) is creating recommendations for gender transition medical care, prompted by a 2021 request from the Ministry of Health. A leak of preliminary recommendations sparked controversy and a complaint.

Leaked French Gender Transition Guidelines Spark Controversy
The French High Authority of Health (HAS) is creating recommendations for gender transition medical care, prompted by a 2021 request from the Ministry of Health. A leak of preliminary recommendations sparked controversy and a complaint.
Progress
44% Bias Score
Showing 1 to 2 of 2 results